"10.1371_journal.pone.0073361","plos one","2013-09-05T00:00:00Z","Nieves Velez de Mendizabal; Matthew M Hutmacher; Iñaki F Troconiz; Joaquín Goñi; Pablo Villoslada; Francesca Bagnato; Robert R Bies","Indiana University School of Medicine; Indianapolis, Indiana, United States of America; Indiana Clinical and Translational Sciences Institute (CTSI), Indianapolis, Indiana, United States of America; Ann Arbor Pharmacometrics Group (A2PG), Ann Arbor, Michigan, United States of America; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain; Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, United States of America; Center for Neuroimmunology, Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Barcelona, Spain; Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, United States of America; Department of Neurology, University of Maryland, Baltimore, Maryland, United States of America","Conceived and designed the experiments: NVM IFT. Performed the experiments: FB. Analyzed the data: NVM. Contributed reagents/materials/analysis tools: NVM MMH JG. Wrote the paper: NVM RRB MMH. Interpretation of results: PV FB.","Nieves Velez de Mendizabal and Robert R. Bies were supported through Eli Lilly and Company through the Indiana Clinical and Translational Sciences Institute (CTSI). Matthew M. Hutmacher is employed by Ann Arbor Pharmacometrics Group (A2PG). There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","09","Nieves Velez de Mendizabal","NVDM",7,TRUE,2,1,1,3,TRUE,TRUE,FALSE,0,NA,FALSE
